Cancer BiologyJournal of Clinical InvestigationPeer-reviewed
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas
Yaniv Kazansky, Helen S. Mueller, Daniel Cameron…·Alex Kentsis
The paper identifies ATR as a target for combination EZH2 epigenetic therapy in SMARCB1-deficient sarcomas, showing that EZH2 inhibition promotes DNA damage via PGBD5, and that ATR inhibition enhances therapeutic responses.
8 citations